Future Medicine  Co., Ltd. Logo

Future Medicine Co., Ltd.

Clinical-stage biopharma developing novel synthetic drugs for inflammation, fibrosis, and oncology.

341170 | KO

Overview

Corporate Details

ISIN(s):
KR7341170009
LEI:
Country:
South Korea
Address:
경기도 성남시 수정구 창업로 54 619호, 성남시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Future Medicine Co., Ltd. is a clinical-stage biopharmaceutical company focused on the development of novel synthetic drugs. The company utilizes its proprietary FOCUSTM (Futuremedicine Origin Compound Universal System) platform, a technology based on nucleoside chemistry, to discover and regulate various in vivo targets. Its therapeutic pipeline addresses unmet medical needs in areas such as inflammation and fibrosis, including treatments for diabetic nephropathy and primary biliary cholangitis (PBC), as well as oncology.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-06-23 00:00
Regulatory News Service
기업설명회(IR)개최결과
Korean 6.6 KB
2025-06-17 00:00
Regulatory News Service
본점소재지변경
Korean 5.1 KB
2025-06-09 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 7.0 KB
2025-03-28 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 20.7 KB
2025-03-28 00:00
Board/Management Information
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Korean 9.9 KB
2025-03-20 00:00
Audit Report / Information
감사보고서제출
Korean 16.0 KB
2025-03-20 00:00
Audit Report / Information
사업보고서 (2024.12)
Korean 333.9 KB
2025-03-13 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 164.6 KB
2025-03-13 00:00
Pre-Annual General Meeting Information
주주총회소집결의
Korean 10.8 KB
2025-03-13 00:00
Pre-Annual General Meeting Information
주주총회집중일개최사유신고
Korean 5.1 KB
2024-12-16 00:00
Pre-Annual General Meeting Information
주주명부폐쇄기간또는기준일설정
Korean 4.1 KB
2024-12-06 00:00
Share Issue/Capital Change
[기재정정]주식매수선택권부여에관한신고
Korean 22.8 KB
2024-11-29 00:00
Regulatory News Service
기업설명회(IR)개최결과
Korean 6.6 KB
2024-11-21 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 7.0 KB
2024-07-19 00:00
Share Issue/Capital Change
[기재정정]주식매수선택권부여에관한신고
Korean 23.0 KB

Automate Your Workflow. Get a real-time feed of all Future Medicine Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Future Medicine Co., Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Future Medicine Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

LISATA THERAPEUTICS, INC. Logo
Oncology firm with a platform for more effective, targeted delivery of anti-cancer drugs.
United States of America
LSTA
LIXTE BIOTECHNOLOGY HOLDINGS, INC. Logo
Developing novel PP2A inhibitors to enhance cancer therapies and overcome treatment resistance.
United States of America
LIXT
Longeveron Inc. Logo
Develops cell therapies for Alzheimer's, aging frailty, and rare infant heart defects.
United States of America
LGVN
Lonza Group AG Logo
A leading CDMO for pharma, biotech & nutrition, providing end-to-end development & manufacturing.
Switzerland
LONN
Lyell Immunopharma, Inc. Logo
Develops durable CAR T-cell therapies for solid tumors & blood cancers by reprogramming T-cells.
United States of America
LYEL
Lyra Therapeutics, Inc. Logo
Developing localized, long-acting therapies for chronic rhinosinusitis (CRS).
United States of America
LYRA
Lytix Biopharma AS Logo
Develops oncolytic peptide immunotherapies that kill cancer and stimulate an anti-tumor response.
Norway
LYTIX
MaaT Pharma Logo
Developing gut microbiome therapies to improve survival for cancer patients.
France
MAAT
Mabion S.A. Logo
Global CDMO providing end-to-end services for developing and manufacturing complex biologic drugs.
Poland
MAB
MACROGENICS INC Logo
Biopharma firm developing innovative antibody-based therapeutics for cancer treatment.
United States of America
MGNX

Talk to a Data Expert

Have a question? We'll get back to you promptly.